Antiulcer drugs and gastric cancer

Digestive Diseases and Sciences

Volumn 50, Issue SUPPL. 1, 2005, Pages

  Waldum, Helge L ^a,b   Gustafsson, Bjørn ^a   Fossmark, Reidar ^a   Qvigstad, Gunnar ^a  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

ECL cell; Gastric acid; Gastrin; Inhibitors of acid secretion

Indexed keywords

ANTACID AGENT; ANTIULCER AGENT; GASTRIN; HISTAMINE H2 RECEPTOR ANTAGONIST; LOXTIDINE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RANITIDINE;

CARCINOGENESIS; CELL PROLIFERATION; DISEASE DURATION; ENTEROCHROMAFFIN CELL; HELICOBACTER FELIS; HELICOBACTER PYLORI; HUMAN; HYPERGASTRINEMIA; NONHUMAN; PERNICIOUS ANEMIA; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; STOMACH ACID SECRETION; STOMACH CARCINOMA; STOMACH PH; STOMACH ULCER; ZOLLINGER ELLISON SYNDROME;

ANTI-ULCER AGENTS; CARCINOMA; DRUG ADMINISTRATION SCHEDULE; ENTEROCHROMAFFIN CELLS; GASTRIC ACID; GASTRINS; HUMANS; STOMACH NEOPLASMS;

EID: 25644456041     PISSN: 01632116     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10620-005-2805-4     Document Type: Review

References (74)

1. Moss SF, Calam J: Acid secretion and sensitivity to gastrin in patients with duodenal ulcer: Effect of eradication of Helicobacter pylori. Gut 34:888-892, 1993
2. Bodemar G, Walan A: Maintenance treatment of recurrent peptic ulcer by cimetidine. Lancet 1:403-407, 1978
3. Majumdar SR, Soumerai SB, Farraye FA, Lee M, Kemp JA, Henning JM, Schrammel P, LeCates RF, Ross-Degnan D: Chronic acid-related disorders are common and underinvestigated. Am J Gastroenterol 98:2409-2414, 2003
4. Howden CW, Castell DO, Cohen S, Freston JW, Orlando RC, Robinson M: The rationale for continuous maintenance treatment of reflux esophagitis. Arch Int Med 155:1465-1471, 1995
5. Howson CP, Hiyama T, Wynder EL: The decline in gastric cancer: Epidemiology of an unexplained triumph. Epidemiol Rev 8:1-27, 1986
6. Haenszel W, Kurihara M, Segi M, Lee RK: Stomach cancer among Japanese in Hawai. J Natl Cancer Inst 49:969-988, 1972
7. Konjetzny GE: Ueber d. Besichungen d. chronischen Gastritis mit ihren Folgeerscheinungen und d. chronischen Magenulcus zur Entwicklung des Magenkrebses. Beitr Klin Chir 85:455, 1913
8. Kokkola A, Sjøblom SM, Haapiainen R, Sipponen P, Puolakkaimen P, Järvinen H: The risk of gastric carcinoma and carcinoid tumours in patients with pernicious anaemia. A prospective followup study. Scand J Gastroenterol 33:88-92, 1998
9. Svendsen JH, Dahl C, Svendsen LB, Christiansen PM: Gastric cancer risk in achlorhydric patients: A long-term follow-up study. Scand J Gastroenterol 21:16-20, 1986
10. El-Omar EM, Oien K, El-Nujumi A, Gillen D, Wiez A, Fahill S, Williams C, Ardill JES, McColl KEL: Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 113:15-24, 1997
11. The Eurogast Study Group. An international association between Helicobacter pylori infection and gastric cancer. Lancet 341:1359-1362, 1993
12. Levi S, Beardshall K, Swift I, Foulkes W, Playford R, Ghosh P, Calam J: Antral Helicobacter pylori, hypergastrinaemia, and duodenal ulcers: effect of eradicating the organism. BMJ 299:1504-1505, 1989
13. Hansson L-E, Nyrén O, Hsing AW, Bergström R, Josefsson S, Chow W-H, Fraumeni JF, Adami H-O: The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med 335:242-249, 1996
14. Katelaris PH, Seow F, Lin BPC, Napoli J, Ngu MC, Jones DB: Effect of age. Helicobacter pylori infection, and gastritis with atrophy on serum gastrin and gastric acid secretion in healthy men. Gut 1993, 34: 1032-1037.
15. Correa P, Miller MJS: Helicobacter pylori and gastric atrophy - cancer paradoxes. J Natl Canc Inst 87:173-174, 1995
16. Mirvish SS: The etiology of gastric cancer: intragastric nitrosamide formation and other theories. J Ntl Cancer Inst 71:629-647, 1983
17. Mirvish SS: Idem. Human gastric carcinogenesis: multistep and multifocal process - first American Cancer Society award lecture on cancer epidemiology and prevention. Cancer Res 52:6735-6740, 1992
18. Zamcheck N, Grable E, Ley A, Normal L: Occurrence of gastric cancer among patients with pernicious anemia at the Boston City Hospital. N Engl J Med 252:1103-1110, 1955
19. Waldum HL, Petersen H, Brenna E: Gastrin and gastric cancer. Eur J Gastroenterol Hepatol 4:801-811, 1992
20. Trudeau WL, McGuigan JE: Relations between serum gastrin levels and rates of gastric hydrochloric acid secretion. N Engl J Med 284:408-412, 1971
21. Crean GP, Marshall MW, Rumsey RDE: Parietal cell hyperplasia induced by the administration of pentagastrin (ICI 50, 123) to rats. Gastroenterology 57:147-155, 1969
22. Lehy T, Bonnefond A, Dubrasquet M, Nasca S, Lewin M, Bonfils S: Comparative effects of antrocolic transposition and antrectomy on fundic mucosa and acid secretion of the rat. Gastroenterology 64:421-128, 1973
23. Bakke I, Qvigstad G, Brenna E, Sandvik AK, Waldum HL: Gastrin has a specific proliferative effect on the rat enterochromaffin-like cell, but not on the parietal cell: a study by elutriation centrifugation. Acta Physiol Scand 169:29-37, 2000
24. Bakke I, Qvigstad G, Sandvik AK, Waldum HL: The CCK-2 receptor is located on the ECL cell, but not on the parietal cell. Scand J Gastroenterol 36(11):1128-1133, 2001
25. Berglindh T, Helander HF, Öbrink KJ: Effects of secretagogues on oxygen consumption, aminopyrine accumulation and morphology in isolated gastric glands. Acta Physiol Scand 97:401-114, 1976
26. Waldum HL, Brenna E, Sandvik AK: Relationship of ECL cells and gastric neoplasia. Yale J Biol Med 71:325-335, 1998
27. Higham AD, Bishop LA, Dimaline R, Blackmore CG, Dobbins AC, Varro A, et al.: Mutations of Reglalpha are associated with enterochromaffin-like cell tumor development in patients with hypergastrinemia. Gastroenterology 116:1310-1318, 1999
28. Solcia E, Capella C, Fiocca R, Rindi G, Rosai J: Gastric argyrophil carcinoidosis in patients with Zollinger-Ellison syndrome due to type I multiple endocrine neoplasia. A newly recognized association. Am J Surg Pathol 14:503-513, 1990
29. Borch K, Renevall H, Liedberg G: Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia. Gastroenterology 88:638-648, 1985
30. Bordi C, D'Adda T, Pilato FP, Ferrari C: Carcinoid (ECL cell) tumor of the oxyntic mucosa of the stomach: a hormone-dependent neoplasm? In Progress in Surgical Pathology. C Fenoglio-Preiser, M Wolf, R Rilke, (eds.). Philadelphia PA, Field & WOOD, vol. 8, 1988, pp 177-195
31. Poynter D: Long-term effects of reduced gastric acidity in laboratory animals. Digestion 31:174, 1985
32. Havu N: Enterochromaffin-like cell carcinoids of gastric mucosa in rats after life-long inhibition of gastric acid secretion. Digestion 35:42-55, 1986
33. 2 blockade and gastric carcinoid tumours in the rat. Gut 26:1284-1295, 1985
34. Modlin IM, Lye KD, Kidd M: Carcinoid tumors of the stomach. Surg Oncol 12:153-172, 2003
35. Waldum HL, Haugen OA, Isaksen C, Mecsei R, Sandvik AK: Are difuse gastric carcinomas neuroendocrine tumours (ECL-omas)? Eur J Gastroenterol Hepatol 3:245-249, 1991
36. Waldum HL, Aase S, Kwetnoi I, Brenna E, Sandvik AK, Syversen U, et al.: Neuroendocrine differentiation in human gastric carcinoma. Cancer 83:435-444, 1998
37. Qvigstad G, Sandvik AK, Brenna E, Aase S, Waldum HL: Detection of chromogranin A in human gastric adenocarcinomas using a sensitive immunohistochemical technique. J Histochem 32:551-556, 2000
38. Lauren P: The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand 64:31-19, 1965
39. Henson DE, Dittus C, Younes M, Nguyen H, Albores-Saavedra J: Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973-2000. Increase in the signet ring cell type. Arch Pathol Lab Med 128:765-770, 2004
40. Qvigstad G, Falkmer S, Westre B, Waldum HL: Clinical and histopathological tumour progression in ECL cell carcinoids ("ECLomas" ). APMIS 107:1085-1093, 1999
41. Wang TC, Dangler CA, Chen D, Goldenring JR, Koh T, Raychowdhury R, Coffey RJ, Ito S, Varro A, Dockray GJ, Fox JG: Synergistic interaction between hypergastrinemia and Helicobacter infection in a mouse model of gastric cancer. Gastroenterology 118:36-17, 2000
42. Hirayama F, Takagi S, Iwao E, Yokoyama Y, Haga K, Hanada S: Development of poorly differentiated adenocarcinoma and carcinoid due to long-term Helicobacter pylori colonization in Mongolian gerbils. J Gastroenterol 34:450-454, 1999
43. Waldum HL, Brenna E: Hypergastrinemia in patients infected with Helicobacter pylori, treated with proton pump inhibitors. Gut 54:566, 2005
44. Waldum HL, Sandvik AK, Brenna E: Gastrin, the enterochromaffin-like cell and gastric tumors. Gastroenterology 105:1264-1265, 1993
45. Hansen S, Vollset SE, Ardill JES, El-Omar E, Melby K, Aase S, et al.: Hypergastrinemia is a strong predictor of distal gastric adenocarcinoma among Helicobacter pylori infected persons. Gastroenterology 112:A575, 1997
46. Waldum HL, Rørvik H, Falkmer S, Kawase S: ECL cell differentiation of spontaneous gastric carcinomas of cotton rats (Sigmodon hispidus). Lab Anim Sci 49:241-247, 1999
47. Martinsen TC, Kawase S, Håkanson R, Torp SH, Fossmark R, Qvigstad G, Sandvik AK, Waldum HL: Spontaneous ECL cell carcinomas in cotton rats: natural course and prevention by a gastrin receptor antagonist. Carcinogenesis 24:1887-1896, 2003
48. Fossmark R, Martinsen TC, Bakkelund KE, Kawase S, Waldum HL: ECL-cell derived gastric cancer in male cotton rats dosed with the H2-blocker loxtidine. Cancer Res 15:3687-3693, 2004
49. Martinsen TC, Nesjan N, Rønning K, Sandvik AK, Waldum HL: The peroxisome-proliferator ciprofibrate induces hypergastrinemia without raising gastric pH. Carcinogenesis 17:2153-2155, 1996
50. Spencer AJ, Barbolt TA, Henry DC, Eason CT, Sauerschell RJ, Bonner FW: Gastric morphological changes including carcinoid tumours in animals treated with a potent hypolipidaemic agent, ciprofibrate. Toxicol Pathol 17:7-15, 1989
51. Martinsen TC, Bergh K, Waldum HL: Gastric juice: A barrier against infectious diseases. J Pharmacol Toxicol 96:94-102, 2005
52. Walsh JW, Richardson CT, Fordtran JS: pH dependence of acid secretion and gastrin release in normal and ulcer subjects. J Clin Invest 55:462-468, 1975
53. Blair AJ, Richardson CT, Walsh JN, Feldman M: Variable contribution of gastrin to gastric acid secretion after a meal in humans. Gastroenterology 92:944-999, 1987
54. Wilder-Smith CH, Spirig C, Krech T, Merk HS: Bactericidal factors in gastric juice. Eur J Gastroenterol Hepatol 4:885-891, 1992
55. Havu N, Mattsson H, Ekman L, Carlsson E: Enterochromaffin-like cell carcinoids in the rat gastric mucosa following long-term administration of ranitidine. Digestion 45:189-195, 1990
56. Lanzon-Miller S, Pounder RE, Hamilton MR, Ball S, Chronos NAF, Raymond F, Olausson M, Cederberg C: Twenty-four-hour intragastric acidity and plasma gastrin concentration before and during treatment with either ranitidine or omeprazole. Aliment Pharmacol Ther 1:239-251, 1987
57. Marks RD, Richter JE, Rizzo J, Hoehler RE, Spenney JG, Mills TP, Champion G: Omeprazole versus H2-receptor antagonists in treating patients with peptic stricture and esophagitis. Gastroenterology 106:907-915, 1994
58. 2-blockade placebo-controlled studies of 24-hour acidity and gastrin. Aliment Pharmacol Ther 4:47-63, 1990
59. Sandvik AK, Brenna E, Waldum HL: Rewiev article: the pharmacological inhibition of gastric acid secretion - tolerance and rebound. Aliment Pharmacol Ther 11:1013-1018, 1997
60. Waldum HL, Arnestad JS, Brenna E, Eide I, Syversen U, Sandvik AK: Marked increase in gastric acid secretory capacity after omeprazole treatment. Gut 39:649-653, 1996
61. Lamberts R, Creutzfeldt W, Stockmann F, Jacubaschke U, Maas S, Brunner G: Long-term omeprazole treatment in man: effects on gastric endocrine cell population. Digestion 39:126-135, 1988
62. Schenk BE, Kuipers EJ, Klinkenberg-Knol EC, Bloemena E, Nelis GF, Festen HPM, Jansen EH, Biemond I, Lamers CBHW, Meuwissen SGM: Hypergastrinaemia during long-term omeprazole therapy: Influences of vagal nerve function, gastric emptying and Helicobacter pylori infection. Aliment Pharmacol Ther 12:605-612, 1998
63. Hsing AW, Hansson LE, McLaughlin JK, et al.: Pernicious anemia and subsequent cancer: a population-based cohort study. Cancer 71:745-750, 1993
64. Qvigstad G, Qvigstad T, Westre B, Sandvik AK, Brenna E, Waldum HL: Neuroendocrine didfferentiation in gastric adenocarcinomas associated with severe hypergastrinemia and/or pernicious anemia. APMIS 110:132-139, 2002
65. Lehy T, Cadiot G, Mignon M, Ruszniewski P, Bonfils S: Influence of multiple endocrine neoplasia type 1 on gastric endocrine cells in patients with the Zollinger-Ellison syndrome. Gut 33:1275-1279, 1992
66. Cadiot G, Vissuzaine C, Potet F, Mignon M: Fundic agyrophil carcinoid tumor in a patient with sporadic-type Zollinger-Ellison syndrome. Dig Dis Sci 40:1275-1278, 1995
67. Feurle GE: Argyrophil cell hyperplasia and a carcinoid tumour in the stomach of a patient with sporadic Zollinger-Ellison syndrome. Gut 35:275-277, 1994
68. 2 receptor antagonist and proton pump inhibitor.Dig Dis Sci 43:253-257, 1998
69. Procter Gamble Company/AstraZeneca LP: Omeprazole magnesium tables. NDA 21:229, 2000
70. Waldum HL: Letter to the editor. Aliment Pharmacol Ther 15:729-730, 2001
71. Brenna E, Waldum HL: Trophic effect of gastrin on the enterochromaffin-like cells of the rat stomach: establishment of a dose response relationship. Gut 33:1303-1306, 1992
72. Sjöblom S-M, Sipponen P, Karonen S-L, Järvinen HJ: Argyrophil cell hyperplasia and carcinoid tumours in oxyntic mucosa of the stomach. Dependence on duration of pernicious anaemia. Eur J Gastroenterol Hepatol 31:153-157, 1991
73. Waldum HL, Brenna E: Personal review: is profound acid inhibition safe? Aliment Pharmacol Ther 14:15-22, 2000
74. Waldum HL, Brenna E, Sandvik AK: Long-term safety of proton pump inhibitors: risks of gastric neoplasia and infections. Expert Opin Drug Saf 1:29-38, 2002